Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
116
-
Total 13F shares, excl. options
-
35M
-
Shares change
-
+4.37M
-
Total reported value, excl. options
-
$1.25B
-
Value change
-
+$169M
-
Put/Call ratio
-
1.93
-
Number of buys
-
77
-
Number of sells
-
-26
-
Price
-
$35.75
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2017
137 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2017.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 116 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 35M shares
of 105M outstanding shares and own 33.41% of the company stock.
Largest 10 shareholders include Essex Woodlands Management, Inc. (3.84M shares), WELLINGTON MANAGEMENT GROUP LLP (3.57M shares), JPMORGAN CHASE & CO (3.56M shares), FRANKLIN RESOURCES INC (3.39M shares), NovaQuest Capital Management, L.L.C. (3.1M shares), BlackRock Inc. (2.17M shares), Bank of New York Mellon Corp (2.14M shares), ArrowMark Colorado Holdings LLC (1.74M shares), Vanguard Group Inc (1.24M shares), and MILLENNIUM MANAGEMENT LLC (1.1M shares).
This table shows the top 116 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.